市場調査レポート

商品コード

1663123

がん性疼痛の市場規模、シェア、成長分析：薬剤クラス別、適応症別、流通チャネル別、投与経路別、エンドユーザー別、地域別 - 産業予測 2025～2032年

Cancer Pain Market Size, Share, and Growth Analysis, By Drug Class (Opioids, Oxycodone), By Indication (Lung cancer, Colorectal Cancer), By Distribution Channel, By Route of Administration, By End User, By Region - Industry Forecast 2025-2032

出版日: 2025年02月19日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 763,518円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 893,172円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,022,826円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.06円

全表示
概要
目次

概要

サンプル依頼リストに入れる

がん性疼痛の世界市場規模は2023年に75億米ドルと評価され、2024年の79億2,000万米ドルから2032年には122億5,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは5.6％で成長する見通しです。

世界のがん性疼痛市場は、がん罹患率の増加、人口動態の高齢化、ヘルスケア支出の増加、ヘルスケア企業による研究開発イニシアチブの高まりなど、いくつかの重要な要因によって大きな成長を遂げています。国際がん研究機関によると、2020年には米国で約180万人が新たにがんと診断され、約606,520人ががんに関連した死亡者数を記録しました。高齢化社会は様々ながんに対して特に脆弱であり、診断年齢の中央値は、乳がんで61歳、大腸がんで68歳、肺がんで70歳、前立腺がんで66歳と報告されています。

北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ

競合情報

上位5社の比較
主要企業の市場ポジショニング（2024年）
主な市場企業が採用した戦略
最近の市場動向
企業の市場シェア分析（2024年）
主要企業の企業プロファイル
- 企業の詳細
- 製品ポートフォリオ分析
- 企業のセグメント別シェア分析
- 収益の前年比比較（2022-2024）

主要企業プロファイル

Pfizer（USA）
Johnson & Johnson（USA）
Purdue Pharma（USA）
Novartis（Switzerland）
Heron Therapeutics（USA）
Teva Pharmaceutical Industries（Israel）
Eli Lilly and Company（USA）
AstraZeneca（UK）
GlaxoSmithKline（UK）
Merck & Co., Inc.（USA）

結論と提言

Product Code: SQMIG35J2075

Global Cancer Pain Market size was valued at USD 7.5 billion in 2023 and is poised to grow from USD 7.92 billion in 2024 to USD 12.25 billion by 2032, growing at a CAGR of 5.6% during the forecast period (2025-2032).

The global cancer pain market is experiencing significant growth, driven by several key factors: the increasing prevalence of cancer, an aging demographic, rising healthcare expenditures, and heightened research and development initiatives by healthcare companies. In 2020, the American Cancer Society noted approximately 1.8 million new cancer diagnoses and about 606,520 cancer-related fatalities in the U.S. Moreover, colorectal cancer was responsible for around 1,065,960 new cases globally, according to the International Agency for Research on Cancer. The aging population is particularly vulnerable to various cancers, with median diagnosis ages reported as 61 for breast cancer, 68 for colorectal cancer, 70 for lung cancer, and 66 for prostate cancer, as highlighted by the National Cancer Institute.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Pain market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Pain Market Segments Analysis

Global Cancer Pain Market is segmented by Drug Class, Indication, Distribution Channel, Route of Administration, End User and region. Based on Drug Class, the market is segmented into Opioids, Oxycodone, Hydrocodone, NSAIDs, Ibuprofen, Naproxen and Others. Based on Indication, the market is segmented into Lung cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Blood Cancer and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Online Pharmacy and Retail Pharmacy. Based on Route of Administration, the market is segmented into Oral, Parenteral and Others. Based on End User, the market is segmented into Hospitals, Homecare, Specialty Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cancer Pain Market

The Global Cancer Pain market is significantly driven by technological advancements in pain management strategies, innovative drug delivery systems, and the development of personalized treatment options. These innovations not only improve the effectiveness of pain relief methods but also make them more accessible to patients suffering from cancer-related pain. As research and development continue to evolve, the emergence of new technologies is expected to optimize patient outcomes, streamline treatment protocols, and ensure that individuals have better access to the most suitable pain management solutions for their unique needs. This dynamic landscape continues to shape the market and enhance the quality of life for those affected.

Restraints in the Global Cancer Pain Market

The growth of the global cancer pain market may be hampered by the risks of drug tolerance and dependence that can arise from the use of pain medications, along with the possibility of experiencing a range of side effects. These factors contribute to concerns among healthcare providers and patients alike, potentially influencing their willingness to utilize certain pharmacological interventions. Additionally, the fear of adverse reactions may prompt individuals to seek alternative pain management strategies, further restricting the market's expansion. Consequently, addressing these challenges is essential for promoting a more favorable environment for growth within this crucial sector.

Market Trends of the Global Cancer Pain Market

The Global Cancer Pain market is witnessing a significant trend towards personalized pain management, driven by an increasing emphasis on individualized treatment strategies that leverage genetic and molecular profiling. This shift reflects a broader movement in healthcare to tailor therapies to the unique characteristics of patients, enhancing the efficacy and outcome of pain management in cancer care. By integrating advanced diagnostics and biomarker analysis, stakeholders in the market are innovating targeted pain relief solutions designed to optimize patient comfort and overall quality of life. This trend is expected to accelerate growth in the market, fostering advancements in treatment protocols and patient adherence.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Studies
Regulatory Analysis
Technology Analysis

Global Cancer Pain Market Size by Drug Class & CAGR (2025-2032)

Market Overview
Opioids
Oxycodone
Hydrocodone
NSAIDs
Ibuprofen
Naproxen
Others

Global Cancer Pain Market Size by Indication & CAGR (2025-2032)

Market Overview
Lung cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Blood Cancer
Others

Global Cancer Pain Market Size by Distribution Channel & CAGR (2025-2032)

Market Overview
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy

Global Cancer Pain Market Size by Route of Administration & CAGR (2025-2032)

Market Overview
Oral
Parenteral
Others

Global Cancer Pain Market Size by End User & CAGR (2025-2032)

Market Overview
Hospitals
Homecare
Specialty Clinics
Others

Global Cancer Pain Market Size & CAGR (2025-2032)

North America (Drug Class, Indication, Distribution Channel, Route of Administration, End User)
- US
- Canada
Europe (Drug Class, Indication, Distribution Channel, Route of Administration, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Drug Class, Indication, Distribution Channel, Route of Administration, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Drug Class, Indication, Distribution Channel, Route of Administration, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Drug Class, Indication, Distribution Channel, Route of Administration, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Pfizer (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Purdue Pharma (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Heron Therapeutics (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

がん性疼痛の市場規模、シェア、成長分析：薬剤クラス別、適応症別、流通チャネル別、投与経路別、エンドユーザー別、地域別 - 産業予測 2025～2032年

Cancer Pain Market Size, Share, and Growth Analysis, By Drug Class (Opioids, Oxycodone), By Indication (Lung cancer, Colorectal Cancer), By Distribution Channel, By Route of Administration, By End User, By Region - Industry Forecast 2025-2032

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

がん性疼痛市場規模：薬剤クラス別& CAGR（2025-2032）

がん性疼痛市場規模：適応症別& CAGR（2025-2032）

がん性疼痛市場規模：流通チャネル別& CAGR（2025-2032）

がん性疼痛市場規模：投与経路別& CAGR（2025-2032）

がん性疼痛市場規模：エンドユーザー別& CAGR（2025-2032）

がん性疼痛市場規模：地域別& CAGR（2025-2032）